CClinicalTrials.gg
CompletedNCT06052982SADUpdated Sep 25, 2023

Evaluation of Blood Loss During Knee Arthroplasty

An interventional study of Drainage in Primary Knee Arthroplasty, sponsored by Groupe Hospitalier Diaconesses Croix Saint-Simon. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-25.

Sponsored by Groupe Hospitalier Diaconesses Croix Saint-Simon · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Apr 2022, registered Mar 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Primary arthroplasties are frequent interventions that can present hemorrhagic complications: postoperative hematoma, deglobulization justifying monitoring blood tests and blood transfusion if necessary.

The attitude regarding the drainage of the surgical site supposed to limit these events differs from one surgeon to another, even in the same team. Its use is common practice; for some, systematic. For others, depending on intraoperative findings or the patient's condition. For others, the drain is never laid.

Faced with the divergence of data from the literature on the benefit of the placement of a drain for intra and postoperative bleeding in knee arthroplasty, the lack of randomized prospective studies on large series of patients, and in a desire to homogenization and standardization of the operating procedure of our surgeons, investigators decided to conduct this prospective interventional, comparative and randomized study.

Read the detailed description

After obtaining the patient's consent and randomisation, the operating surgeon will have the information of placing or not a drain, lately at the end of the intervention so that the course of the intervention is not influenced by the prior knowledge of the patient randomization arm.

Investigators will carry out especially within the framework of this research 3 samples of a total of 10.7 ml of whole blood (appendix. 12.5) distributed as follows:

Sample no. 1 : 2.7 ml of blood in a hemostasis tube (sodium citrate tube) one day before the procedure (D-1) for the determination of the prothrombin level (PT), activated partial thromboplastin time ( TCA) and the INR or International Normalized Ratio.

Sample no. 2 : 4 ml of blood in a purple EDTA tube for NFS, one day before the operation (D-1) for the determination of hemoglobin ( Hb ) and hematocrit ( Hct ) Sample no. 3 : 4 ml of blood in a violet EDTA tube for NFS for the determination of hemoglobin ( Hb ) and hematocrit ( Hct ) on the fifth postoperative day (D5). This last assessment will be prescribed to the patient to be carried out in the rehabilitation center..

The knee prosthesis implantation surgical technique is performed according to the standard operating procedure of the orthopedic surgery team.

According to the operating standard procedure of our orthopedic department, the drain is non-aspirated for 6 hours and then put back under vacuum until the morning after the knee prosthesis operation.

Three months after the intervention the patient will be seen again in consultation and examined.

02

Conditions studied

  • Primary Knee Arthroplasty

Browse trials for

Keywords

  • Blood
  • Loss
  • Drainage
  • Without drainage
03

In context

Hemorrhage

3,000 studies on the registry are indexed under Hemorrhage; 474 are open to participants now.

This study's enrollment of 510 is above the median of 100 across 1,985 interventional studies indexed under Hemorrhage.

Browse Hemorrhage studies →

Lead sponsor

Groupe Hospitalier Diaconesses Croix Saint-Simon is the lead sponsor of 26 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient consent
  • Patient aged over 18 years
  • Patient scheduled for primary knee arthroplasty

Exclusion criteria

Exclusion Criteria:

  • Patient expresses his/her opposition to participating in the study
  • Patient scheduled for revision, revision or totalization arthroplasty
  • Primary arthroplasty after septic arthritis
  • Patient requiring an additional planned or unplanned surgical procedure such as TTTA, osteosynthesis for an intraoperative fracture and/or removal of material
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
510 participants (actual)

Study arms

  • Other
    Drain

    At the end of the knee arthroplasty, a drain is placed at the surgical site

    Procedure: Drainage

  • Other
    Without drain

    At the end of the knee arthroplasty, a drain is not placed at the surgical site

    Procedure: Drainage

Interventions

  • ProcedureDrainage

    At the end of the knee arthroplasty, a drain is placed or not at the surgical site depending on randomization result

06

What researchers measure

Primary outcomes

  1. Hemoglobin dosage and bleeding quantification in both groups

    Estimation of blood loss with Mercuriali Formula. This formula requires the patient's blood volume and requires the volume of red blood cells transfused as well.

    Time frame: from the day before surgery until the 5th postoperative day

Secondary outcomes

  1. Assessment of blood transfusion during primary knee arthroplasty

    Measurement of total blood transfused between surgery and the fifth day after surgery

    Time frame: from surgery until the 5th postoperative day

  2. Number of patients with complications after knee arthroplasty in the two groups

    Monitoring for complications from surgery up to 3 months

    Time frame: From surgery up to the third month

07

Study locations

1 site
  • Groupe Hospitalier Diaconesses Croix Saint Simon
    Paris, Ile De France 75020, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06052982
Lead sponsor
Groupe Hospitalier Diaconesses Croix Saint-Simon
Responsible party
Dr LHOTELLIER Luc (Orthopedic surgeon, Groupe Hospitalier Diaconesses Croix Saint-Simon) — Principal investigator
First posted
Sep 25, 2023
Start date
Apr 10, 2022
Primary completion
Apr 10, 2023
Completion
Jul 10, 2023
Last update
Sep 25, 2023

Study contacts

Luc LHOTELLIER, MD
principal investigator · Groupe Hospitalier Diaconesses Croix Saint-Simon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion